BioMarin Pharmaceutical | BMRN - Trade Debtors


BioMarin Pharmaceutical reported $903.91M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amgen USD 9.14B 432M Mar/2026
Bayer EUR 18.55B 4.36B Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
Insmed USD 178.55M 37.7M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Moderna USD 71M 113M Mar/2026
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026